The stock of Merck & Co Inc (NYSE:MRK) last traded at $91.27, up 1.98% from the previous session.
MRK stock price is now -4.69% away from the 50-day moving average and -18.10% away from the 200-day moving average. The market capitalization of the company currently stands at $230.88B.
With the price target reduced from $128 to $105, Deutsche Bank Downgraded its rating from Buy to Hold for Merck & Co Inc (NYSE: MRK). On February 10, 2025, TD Cowen Downgraded its previous ‘Buy’ rating to ‘Hold’ on the stock reducing its target price from $121 to quote $100, while ‘Truist’ rates the stock as ‘Hold’
In other news, Oosthuizen Johannes Jacobus, President, U.S. Market sold 8,500 shares of the company’s stock on Feb 19 ’25. The stock was sold for $714,745 at an average price of $84.09. Upon completion of the transaction, the President, U.S. Market now directly owns 30,705 shares in the company, valued at $2.8 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Feb 19 ’25, Officer JOHANNES JACOBUS OOSTHUIZEN bought 8,500 shares of the business’s stock. A total of $714,745 was incurred on buying the stock at an average price of $84.09. A total of 0.09% of the company’s stock is owned by insiders.
During the past 12 months, Merck & Co Inc has had a low of $81.04 and a high of $134.63. As of last week, the company has a debt-to-equity ratio of 0.86, a current ratio of 1.36, and a quick ratio of 1.15.
The net profit margin was 26.62% and return on equity was 28.33% for MRK. The company reported revenue of $15.62 billion for the quarter, compared to $14.63 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 6.79 percent.
